1-4-D-Arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) reduced the mortality rates of (i) 7-week-old, cyclophosphamide-treated, immunosuppressed mice (CYP mice) intraperitoneally infected with a moderately virulent strain of herpes simplex virus type 1 and (ii) 4-week-old CYP mice infected with a less virulent strain at doses of 20 and 50 mg/kg of body weight twice daily and 5 mg/kg, respectively. The degree of efficacy of BV-araU was equivalent to that of acyclovir in 4-week-old CYP mice infected with the less virulent strain. BV-araU (20 mg/kg) suppressed viral growth in various organs of CYP mice.
1-f3-D-Arabinofuranosyl-E-5-(2-bromovinyl)uracil (BVaraU) (7) exhibits potent activity against varicella-zoster virus in vitro (4) , and its clinical efficacy for treatment of herpes zoster in immunocompetent patients has been demonstrated (10) . We have demonstrated the marked effectiveness of BV-araU against intracerebral and intraperitoneal (i.p.) infections with herpes simplex virus type 1 (HSV-1) in mice (5a, 6, 8) . For beneficial clinical application of BVaraU, it must have potency for not only immunocompetent individuals but also immunocompromised patients. In this study, we tested the efficacy of BV-araU in immunosuppressed animals and demonstrated its therapeutic efficacies against infection with two HSV-1 strains with different degrees of virulence in cyclophosphamide-treated, immunosuppressed mice (CYP mice) of different ages.
Four-week-old, random-bred, albino male Swiss ICR mice were obtained as previously described (8) . To induce immunosuppression, mice were treated i.p. with 200 mg of cyclophosphamide (Aldrich Chemical Co., Inc.) per kg of body weight 1 day before virus inoculation by the method of Ikeda et al. (2) . Two strains of HSV-1 were used; strain WT-51 was moderately virulent (8) , and strain KOS(S), a substrain of strain KOS (supplied by Y. Ozaki, Shiga University of Medical Science, Shiga-ken, Japan), was avirulent for non-CYP (normal) mice. There was no significant difference between these two strains in susceptibility to BV-araU [50o plaque reduction doses of BV-araU for strains WT-51 and KOS(S) were 0.020 and 0.082 ,uLg/ml, respectively, when assayed on human embryonic lung cells]. Groups of about 20 CYP mice were infected i.p. with strain WT-51 (1.5 x 103 PFU) or KOS(S) (2.2 x 104 PFU). These challenge virus doses corresponded to 8 and 36 50% lethal doses for 4-weekold CYP mice, respectively. After infection with strain WT-51, 85 to 95% of the CYP mice in placebo-treated control groups died. The mortality and mean survival time of CYP mice infected with strain KOS(S) depended upon the age of the mice used. BV-araU was administered orally to infected mice twice daily for 7 days, beginning at 4 h postinfection, as described previously (8) . The mice were observed twice daily for 21 days for death.
To examine the inhibitory effect of BV-araU on HSV-1 replication in the organs of infected animals, four mice from each group were sacrificed at appropriate intervals after i.p. * Corresponding author.
inoculation with strain WT-51. Five organs of infected mice were aseptically removed, weighed, and homogenized with a Potter-Elvehjem homogenizer to make a 10% suspension with sterile phosphate-buffered saline. The homogenates were centrifuged at 1,500 x g for 5 min at 4°C, and the supernatant was frozen at -80°C. To make homogenates of stomach and gut tissues, the organs were washed well with sterile phosphate-buffered saline before and after they were minced. The virus titer of each specimen was determined on immortalized human KMST-6 cells (9).
Oral and i.p. doses of BV-araU up to 800 mg/kg given twice daily for 7 days did not cause death in uninfected CYP mice (data not shown), as with uninfected normal mice (5, Sa) . No toxic signs were observed, except that body weight gain was slightly suppressed in a group that received 800 mg of BV-araU i.p. 
Days after
Treatment with BV-araU at a dose of 100 mg/kg twice daily was effective in decreasing the mortality of CYP mice infected with HSV-1 strain WT-51 (Table 1) . Treatment with 20 and 50 mg/kg, doses at which it reduced the mortality of normal mice (8) , prolonged the mean survival time but did not reduce mortality. Effects of BV-araU against infection with strain KOS(S) were more marked; BV-araU at a dose as low as 5 mg/kg reduced the mortality of infected mice. Most of the CYP mice that received at least 20 mg of BV-araU per kg survived. Thus, the efficacy of BV-araU against infection with strain KOS(S) was more marked than that against infection with strain WT-51, despite the use of a larger viral inoculum. Differences in the minimum effective doses required for reduction of significant mortality for infections with strains WT-51 and KOS(S) may be-related to the degree of virulence of the challenge virus used, as we reported for normal mice (8) . Treatment with 20 mg of BV-araU per kg twice daily led to reduction of the mortality of 7-week-old CYP mice infected with strain WT-51 (Table 2) . Most infected CYP mice that received 50 or 100 mg of BV-araU per kg survived. Furthermore, one-half of the placebotreated CYP mice infected with strain KOS(S) died, while all of the mice given 20 or 50 mg of BV-araU per kg survived. The minimum effective dose for WT-51 infection in 7-weekold CYP mice was about 20 mg/kg. Thus, a higher efficacy of BV-araU against infection with strain WT-51 was found in 7-week-old CYP mice than in 4-week-old mice, although on September 6, 2017 by guest http://aac.asm.org/ Downloaded from there was no difference between 4-and 7-week-old CYP mice in susceptibility to infection. The efficacies of BV-araU and acyclovir were compared in this model. Oral treatment with BV-araU or acyclovir at a dose of 20 mg/kg significantly reduced the mortality of 4-week-old CYP mice infected with KOS(S): the survival rates of the BV-araU-and acyclovir-treated groups were 13 of 20 (P < 0.001) and 8 of 19 (P < 0.02), respectively, while the rate in the control group was 1 of 21. However, in groups of 20 mice that received BV-araU at doses of 1 and 5 mg/kg, 1 and 4, respectively, survived, and of those that received acyclovir, 6 survived. The differences between the survival rates of these groups and that of the control group were not statistically significant.
Changes in virus titers in several organs from CYP mice and normal mice were examined. High virus titers were found only in adrenal gland, spinal cord, and brain tissues, but low levels of the infective virus were found transiently in other organs from normal mice after i.p. infection with 1.5 x 105 PFU of strain WT-51 (data not shown), in agreement with the findings of Hill et al. (1) . In contrast, high levels of infective virus were constantly found in various visceral organs from CYP mice 2 to 6 days postinfection with 1.5 x 103 PFU. Virus titers in the gastrointestinal tracts and adrenal glands of CYP mice at 6 days postinfection were more than 105 PFU, while no virus or a low titer was found in those from normal mice on the same day. In contrast, viral growth in adrenal gland, spinal cord, and brain tissues was strongly suppressed by treatment with 20 mg of BV-araU per kg twice daily (Fig. 1) . Drug-treated CYP mice had no infective virus in these organs at 9 days postinfection. Virus titers in the gastrointestinal tracts of drug-treated mice did not increase for 6 days, and infective virus disappeared at 9 days in about half of the drug-treated mice. The virus titers of placebo-treated mice gradually increased until the mice died at 8 days postinfection. These significant differences in virus titers in spinal cord (4 days), brain (6 days), and gastrointestinal tract (4 and 6 days) tissues between placeboand drug-treated groups (P < 0.01 by Student's t test) probably reflect the marked efficacy of BV-araU against such disseminated HSV-1 infection of CYP mice.
Treatment with cyclophosphamide strongly reduced the ability of the host defense mechanism and made mice susceptible to HSV-1 infection (2, 3). Indeed, most CYP mice died after i.p. infection with an inoculum of moderately virulent strain WT-51 as small as 103 PFU, irrespective of their age. CYP mice were also susceptible to infection with strain KOS(S), which is avirulent for normal mice. Infection of CYP mice is similar to that of immunocompromised patients, although disseminated HSV-1 infection in humans is rare. It can be used as a model of infection with herpesviruses in such patients. Since orally administered BV-araU had marked efficacy against HSV-1 infections of CYP mice and low toxicity, it warrants clinical testing for treatment of herpesvirus infections of immunocompromised patients.
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